Neuren Pharmaceuticals Ltd (ASX: NEU) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Neuren Pharmaceuticals Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $2.71 billion
P/E Ratio 17.29
Dividend Yield 0.00%
Shares Outstanding 129.75 million
Earnings per share 1.201
Dividend per share N/A
Year To Date Return -16.82%
Earnings Yield 5.78%
Franking -
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • Neuren Pharmaceuticals Ltd (ASX: NEU)
    Latest News

    A neon sign says 'Top Ten'.
    Share Gainers

    Here are the top 10 ASX 200 shares today

    It was a mildly positive start to the trading week for ASX shares today.

    Read more »

    a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
    Growth Shares

    A hot ASX stock with 'multiple catalysts' looming is 8% down. Time to buy

    The Blackwattle team is still bullish on these pharmaceutical shares despite a recent sell-off.

    Read more »

    A young man clasps his hand to his head with his eyes closed and a pained expression on his face as he clasps a laptop computer in front of him, seemingly learning of bad news or a poor investment.
    Share Fallers

    Why Inghams, IAG, Neuren Pharmaceuticals, and Pro Medicus shares are sinking today

    These ASX shares are ending the week deep in the red. But why?

    Read more »

    Shot of a senior scientist looking stressed out while working in a lab.
    Healthcare Shares

    This ASX 200 healthcare share is diving 13% as short sellers take aim

    A short seller is describing this company's Daybue product as a 'flop'.

    Read more »

    Male Lab Worker Wearing White Coat Recording Test Results On Computer.
    Share Gainers

    If you'd put $20,000 in this ASX healthcare stock in December 2021, you'd have $257,000 now

    In just over 2 years, these shares have gone gangbusters, allowing its investors to forget about the losses made by…

    Read more »

    Three hikers lift their arms in jubilation as they reach a rocky peak overlooking a sensational view of water and mountains with a blue sky surrounding them.
    Best Shares

    Top ASX shares to buy in February 2024

    The Aussie stock market is scaling new heights. Are you getting in on the action?

    Read more »

    A young girl looks up and balances a pencil on her nose, while thinking about a decision she has to make.
    Investing Strategies

    Is now the right time to buy this ASX 200 stock? Here's my take

    These shares are up 163% over the past year. Is it too late to add to your portfolio?

    Read more »

    Three health professionals at a hospital smile for the camera.
    Healthcare Shares

    3 pharma shares outshining the ASX index today

    The ASX All Ords finished lower on Friday but these three stocks outdid their peers.

    Read more »

    a man with a wide, eager smile on his face holds up three fingers.
    Growth Shares

    'Materially undervalued': 3 ASX shares Elvest is backing for a huge 2024

    Here is a trio of growth stocks that finished 2023 with much fanfare but have plenty left in the tank…

    Read more »

    Happy, tablet or doctor in a laboratory with research results or positive feedback after medical data analysis. Smile, vaccine or healthcare worker reading or working on futuristic science innovation.
    Healthcare Shares

    The Neuren Pharmaceuticals share price is up 100% in 3 months: Can it keep rising?

    This pharma share had a transformational year in 2023. Where next for its shares?

    Read more »

    Smiling woman upside down on a swing with yellow glasses, symbolising passive income.
    Investing Strategies

    Here's how I plan to build a second income in 2024

    An additional source of cash is what many aspire to when ploughing our money into ASX shares.

    Read more »

    A group of office workers pump the air to celebrate
    Best Shares

    The No. 1 ASX 200 shares of each market sector in 2023

    These 11 ASX 200 stocks were the No. 1 shares for price growth in their market sectors in 2023.

    Read more »

    Frequently Asked Questions

    No, Neuren Pharmaceuticals does not pay dividends at this time. 

    Neuren Pharmaceuticals Limited (ASX: NEU) listed on the ASX on 3 February 2005.

    NEU ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Neuren Pharmaceuticals Ltd

    Neuren Pharmaceuticals Limited (ASX: NEU) is a biopharmaceutical company specialising in developing new therapies for neurodevelopmental disorders that emerge in early childhood and are characterised by impaired connections and signalling between brain cells. 

    In March 2023, the US Food and Drug Administration approved DAYBUE™ (trofinetide) for the treatment of Rett syndrome in adults and children two years and older. Neuren's US partner Acadia Pharmaceuticals (NASDAQ: ACAD) holds a worldwide exclusive licence from Neuren for trofinetide. At this time, DAYBUE is the first and only drug approved for the treatment of Rett syndrome. Trofinetide has also demonstrated clinical benefit in a Phase 2 trial in treating Fragile X syndrome.

    Neuren's second product NNZ-2591 is currently in Phase 2 clinical trials for the treatment of Phelan-McDermid syndrome, Angelman syndrome, Pitt Hopkins syndrome, and Prader-Willi syndrome. The drug candidate has shown positive effects in mouse models of each syndrome and was successful in a Phase 1 clinical trial. The number of patients across these four disorders is estimated as five times the number of Rett syndrome patients. There are currently no drugs approved for these conditions, apart from growth hormone to treat some aspects of Prader-Willi. 

    Acadia Pharmaceuticals also holds a worldwide exclusive licence to develop and commercialise NNZ-2591 for Rett syndrome and Fragile X syndrome. Neuren retains worldwide rights to NNZ-2591 in all other indications.

    NEU Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    28 Mar 2024 $21.22 $0.45 2.17% 374,911 $20.76 $21.43 $20.70
    27 Mar 2024 $20.77 $0.53 2.62% 304,897 $20.13 $20.77 $20.13
    26 Mar 2024 $20.24 $-0.29 -1.41% 174,834 $20.53 $20.53 $20.12
    25 Mar 2024 $20.53 $0.31 1.53% 384,754 $20.25 $20.53 $20.00
    22 Mar 2024 $20.22 $-0.54 -2.60% 398,261 $20.60 $20.68 $20.01
    21 Mar 2024 $20.76 $0.15 0.73% 424,157 $20.93 $21.40 $20.65
    20 Mar 2024 $20.61 $0.10 0.49% 354,523 $20.65 $21.07 $20.17
    19 Mar 2024 $20.51 $0.01 0.05% 348,441 $20.44 $20.74 $20.32
    18 Mar 2024 $20.50 $0.26 1.28% 359,169 $19.79 $20.61 $19.75
    15 Mar 2024 $20.24 $0.54 2.74% 791,791 $19.70 $20.25 $19.16
    14 Mar 2024 $19.70 $-0.93 -4.51% 489,213 $20.50 $20.76 $19.70
    13 Mar 2024 $20.63 $-0.50 -2.37% 419,228 $21.00 $21.34 $20.53
    12 Mar 2024 $21.13 $1.06 5.28% 792,521 $20.20 $21.25 $20.10
    11 Mar 2024 $20.07 $0.12 0.60% 370,323 $19.82 $20.42 $19.54
    08 Mar 2024 $19.95 $0.49 2.52% 744,590 $19.89 $20.45 $19.78
    07 Mar 2024 $19.46 $-0.30 -1.52% 917,532 $19.88 $19.90 $19.26
    06 Mar 2024 $19.76 $0.11 0.56% 560,310 $19.66 $20.17 $19.61
    05 Mar 2024 $19.65 $-0.03 -0.15% 530,636 $19.49 $19.80 $19.10
    04 Mar 2024 $19.68 $-0.03 -0.15% 362,082 $19.98 $20.19 $19.68
    01 Mar 2024 $19.71 $0.35 1.81% 842,519 $19.88 $20.48 $19.66
    29 Feb 2024 $19.36 $0.21 1.10% 914,234 $18.91 $19.70 $18.80
    28 Feb 2024 $19.15 $-2.33 -10.85% 2,584,344 $21.25 $21.26 $18.16

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    13 Sep 2023 Joseph(Joe) Basile Buy 5,000 $59,950
    On-market trade.
    14 Jun 2023 Trevor Scott Sell 1,175,000 $15,275,000
    On-market trade.

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Dr Trevor D Scott Non-Executive Director Mar 2002
    Trevor joined the Neuren Board in 2002. He is the founder of T.D. Scott and Co., an accountancy and consulting firm, which he formed in 1988. He is an experienced advisor to companies across a variety of industries. Trevor serves on numerous corporate boards and is chairman of several.
    Ms Dianne Margaret Angus Non-Executive Director Jul 2018
    Dianne joined the Neuren Board in 2018. She has worked as a senior executive and non-executive director within
    the biotechnology, biopharmaceutical and agritech industries for over twenty-five years. She has created numerous
    global industry partnerships which include Prana Biotechnology, Gerolymatos International, Florigene, Suntory &
    Monsanto to yield novel and competitive medical, pharmaceutical and agricultural products. Dianne has successfully
    forged strong partnerships with key medical opinion leaders to create innovative clinical research programs and
    driven the development path for novel neurological pre-clinical agents to late-stage clinical assets before the FDA
    and European regulators. With over fifteen years experience in an ASX and NASDAQ listed company, she has expertise
    in business development, capital raising, investor relations, regulatory affairs and intellectual property, together
    with corporate governance and compliance capabilities. Dianne holds a Masters degree in biotechnology and is a
    registered patent attorney.
    Mr Jonathan (Jon) Charles Pilcher Chief Executive OfficerManaging Director Aug 2013
    Jon joined Neuren in 2013 as CFO and was appointed CEO in May 2020. He has played a central role in all aspects of Neuren s R&D, commercial and corporate activities. Before joining Neuren he was a member of the leadership team at Acrux (ASX: ACR) throughout a period that included Acruxs IPO and listing on the ASX, the development and FDA approval of three novel pharmaceutical products and a transforming licensing deal with Eli Lilly in 2010. He formerly spent seven years in a series of executive positions in the R&D and corporate functions of international pharmaceutical groups Medeva and Celltech, which are now part of UCB. Jon is a Chartered Accountant and holds a degree in Biotechnology from the University of Reading in the UK. He is a non executive director of BTC Health Limited (ASX: BTC).
    Dr Jenny Lee Harry Non-Executive Director Jul 2018
    Jenny joined the Neuren Board in 2018. She has 20 years experience in executive management of companies in the
    biotechnology and biopharmaceutical industry. Jenny is an accomplished CEO and Managing Director with experience
    in growing companies from start up to commercialisation. She has served on Boards of a number of listed and unlisted
    companies and is currently a Non Executive Director of Aeris Environmental Limited (ASX:AEI) and on the Boards IP
    sub-committee of the Childrens Medical Research Institute. Jenny is a graduate of the Harvard Business School General
    Manager Program and the Australian Institute of Company Directors.
    Mr Patrick Davies Non-Executive DirectorNon-Executive Chairman Jul 2018
    Patrick joined the Neuren Board in 2018. He has held executive management roles in the Australian and New Zealand healthcare industry for over twenty five years having performed successfully in senior roles across many industry sectors including pharmacy, primary care, pharmaceutical and consumer products. During his ten year period as Chief Executive Officer of EBOS Group Limited (and previously Symbion), the enterprise value of the group achieved compound annual growth in enterprise value of +20% (from circa $450M to in excess of $3.1B). He is a director on other corporate boards and provides strategic advice to a range of healthcare businesses and investors.
    Mr Joseph(Joe) Basile Non-Executive Director Mar 2023
    Mr Basile has held a number of executive roles in the pharmaceutical industry for over 30 years, most recently as Group CFO at iNova Pharmaceuticals based in Singapore and prior to that with Novartis in senior Finance leadership and Commercial Sales leadership roles in Australia and Asia. Joe has experience in corporate mergers and acquisitions, capital management and overseeing expansion activities .
    Ms Lauren Frazer Chief Financial OfficerCompany Secretary Aug 2020
    -
    Lauren Frazer Chief Financial OfficerCompany Secretary
    -
    LIZA SQUIRES, M.D. Chief Medical Officer
    -
    LARRY GLASS Chief Science Officer
    -
    VIRGINIE DUREZ Senior Director Product Development & Project Management
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    NATIONAL NOMINEES LIMITED 11,810,223 9.35%
    Citicorp Nominees Pty Limited 10,759,990 8.52%
    HSBC CUSTODY NOMINEES (AUSTRALIA) LIMITED 9,174,182 7.27%
    J P Morgan Nominees Australia Pty Limited 8,875,428 7.03%
    HSBC Custody Nominees (Australia) Limited A/C 2 6,639,176 5.26%
    Cameron Richard Pty Ltd 4,206,313 3.33%
    BNP Paribas Noms Pty Ltd 2,710,864 2.15%
    Stuart Andrew Pty Ltd 2,460,000 1.95%
    Essex Castle Limited 2,367,144 1.87%
    Smithley Super Pty Ltd 2,010,000 1.59%
    Linwierik Super Pty Ltd 1,885,000 1.49%
    Sharesies Nominee Limited 1,385,966 1.10%
    Mxb Investments Llc 1,330,000 1.05%
    Dr Trevor Scott 1,000,000 0.79%
    First Colbyco Pty Ltd 790,000 0.63%
    Mjhft Pty Ltd 750,000 0.59%
    Dr Robin Lance Congreve 671,637 0.53%
    Hobson Wealth Custodians Ltd 589,337 0.47%
    Emancipayte Pty Ltd 476,607 0.38%
    Bnp Paribas Nominees Pty Ltd Acf Clearstream 465,450 0.37%

    Profile

    since

    Note